CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 5 enrolled
Drug / intervention
Carbidopa 25 mg +1 moredrug
Likely dose
Carbidopa 25 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT06587217
NCT06587217Phase 2Completed

Neurobiological Drivers of Mobility Resilience: The Dopaminergic System

University of Michigan·interventional·Posted Sep 19, 2024·Updated Apr 14, 2026

In Brief

A Phase 2 clinical trial evaluating Carbidopa 25 mg and Carbidopa-Levodopa 25/100 mg for Parkinsonian Signs in Older Persons. Completed, enrolled 5 participants across 2 sites.

Detailed Summary

Walking with age becomes both slower and less 'automated', requiring more attention and brain resources. As a result, older adults have a greater risk of negative outcomes and falls. There is an urgent need to identify factors that can help compensate for these harmful factors and reduce walking impairments, as there are currently no effective treatments available. Investigators have recently discovered that \~20% of older adults maintain fast walking speed even in the presence of small blood vessel brain changes and leg problems, thus appearing to be protected against these harmful factors. The investigators work suggests that the brain dopamine (DA) system may be a source of this protective capacity. Investigators have also shown that lower levels of dopamine are associated with slow walking. Investigators will be investigating the role of dopamine on slow walking and other parkinsonian signs in this open-label study using detailed clinical assessment, assessment of dopamine activity, and clinical interventions.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States

Timeline

Phase 2CompletedFinished
20252026
First PostedSep 19, 2024
Enrollment StartOct 29, 2024
Primary CompletionApr 3, 2025
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 1.8 years ago

Interventions

Carbidopa 25 mgdrug

Participants will take one 25mg Carbidopa tablet 3 times a day for 10 days.

Carbidopa-Levodopa 25/100 mgdrug

Participants will take one 25/100mg carbidopa-levodopa tablet 3 times a day on days 4-6, then increase to 1.5 tablets 3 times a day on days 7-10.